FOLH1 and cancer: Given the proven overexpression of PSMA in ECs or cancer cells of other solid tumors, attempts are being made to apply PSMA ligand-based RLT to other clinical entities such as gliomas, salivary gland carcinomas, papillary thyroid cancer and hepatocellular carcinoma [74,75,76,77].